Preclinical evaluation of cancer immune therapy using patient‐derived tumor antigen‐specific t cells in a novel xenograft platform

HIGHLIGHTS

• who: Gautam N Shenoy and colleagues from the Department of Microbiology and Immunology at the Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA have published the Article: Preclinical evaluation of cancer immune therapy using patientu2010derived tumor antigenu2010specific T cells in a novel xenograft platform, in the Journal: (JOURNAL)
• what: While this approach has great potential for evaluating immune-based strategies,17,18 it is logistically challenging, requiring up to 12 weeks 2021 | Vol. The authors report a novel mouse model, the Xenomimetic mouse (X-mouse) model, established using patient-derived . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.